-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Neutral on Immunovant, Raises Price Target to $32

Benzinga·04/15/2026 17:46:04
Listen to the news
Goldman Sachs analyst Corinne Johnson maintains Immunovant (NASDAQ:IMVT) with a Neutral and raises the price target from $29 to $32.